Abstract 377P
Background
Human papillomavirus (HPV) associated oropharyngeal squamous cell cancers (OPSCC) are known to have better treatment response and outcome compared with HPV -negative ones. Testing for p16 expression is used as a surrogate for HPV testing. While p16- positive tumours comprise of majority of OPSCC in Western population, p16 -positive tumours in Asian population have remained low.
Methods
Data of Indian patients treated at a single institute between 2016 -2023 was ambispectively analyzed for rate of p16 positivity and clinical outcomes. Staining of ≥70% was considered positive for p16. Data entry and analysis was done using IBM SPSS Statistics v21.0.
Results
Between February 2016 – June 2023, 114 patients were treated, of which 106 had SCC. Majority subsites were tonsil (50, 47.2%), base of tongue (30, 28.3%), and soft palate (15, 14.2%). Testing for p16 was done in 66 patients (62%), of which 19 were p16-positive. Smoking history was noted in 36 patients (34%). Treatment modalities were CTRT for 74 patients (69.8%) and RT alone for 32 (30.2%). IMRT was utilized for majority patients (97, 91.5%). Chemotherapeutic agents were cisplatin for 61 (82.4%, 6 (9.8%) shifted to carboplatin) [3 weekly-9, weekly-52], carboplatin 11 (15%) and cetuximab 2 (3%). Treatment was completed by 101 patients (95.3%) [2 discontinued treatment, 3 died before treatment completion due to non-oncologic causes]. At 3 months, response assessment was done for 94 patients, of which 74 (78.7%) had complete response [14/15 (93.3%) p16-positive, 31/41 (75.6%) p16-negative]; 7 patients (7.4%) had incomplete response while 13 (13.8%) progressed. At median follow-up of 23 months (IQR 11–42); 90 patients were alive, 72 (71.3%) had disease under control. Relapse was seen in 9 patients (p16-positive – 0, p16-negative – 4, untested – 5). Median progression free survival was 17 months (IQR 5-37 months).
Conclusions
While p16 positivity amongst Indian OPSCC patients remains lower than Western counterparts, p16 -positive OPSCC have shown favorable response rates in Indian patients. Association of p16 positivity with improved response rates and fewer relapses in the Indian population warrants investigation in a larger randomized trial.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Amrita Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract